Consensus on Prostate Cancer Treatment of Localized Disease With Very Low, Low, and Intermediate Risk: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).

Autor:	Luz MA; Hospital Erasto Gaertner, Curitiba, Brazil., Guimarães GC; A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil., Nardi AC; Integra Urologia, Bauru, São Paulo., Pompeo ASFL; Faculdade de Medicina do ABC, Santo André, Brazil., Sarkis ÁS; A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil.; Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Nowier A; Heliopolis, Cairo, Egypt., Lima Pompeo AC; Faculdade de Medicina do ABC, Santo André, Brazil., Nardozza A Jr; Universidade Federal de São Paulo, São Paulo, Brazil., Adamy A Jr; Hospital Santa Cruz, Curitiba, Brazil., Carneiro A; Hospital Israelita Albert Einstein, São Paulo, Brazil., Salvajoli BP; Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Benigno BS; Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Freitas CH Jr; A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil., Chade CADC; Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Palhares DMF; Hospital Sírio-Libanês, Brasília, Brazil., Otero DAC; Fundación Clinica Shaio, Bogotá, Colômbia., Neto DCVDS; Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil., Carvalhal EF; Hospital Moinhos de Vento, Porto Alegre, Brazil., Gil E; A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil., Freire de Arruda F; Hospital Sírio-Libanês, São Paulo, Brazil., Korkes F; Faculdade de Medicina do ABC, Santo André, Brazil., Caserta Lemos G; Hospital Israelita Albert Einstein, São Paulo, Brazil., Carvalhal GF; Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil., de Carvalho ÍT; Hospital Israelita Albert Einstein, São Paulo, Brazil., Gimpel IFP; Clinica Santa Maria, Providencia, Chile., Chambô JL; A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil., Pontes J Jr; Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Filho LAR; Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Nogueira LM; Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Wroclawski ML; A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil.; Hospital Israelita Albert Einstein, São Paulo, Brazil., Freitas MRP; Centro Especializado de Oncologia de Florianópolis, Florianópolis, Brazil., Arap MA; Hospital Sírio-Libanês, São Paulo, Brazil., Sadi MV; A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil.; Universidade Federal de São Paulo, São Paulo, Brazil., Bulbul M; American University of Beirut, Beirut, Lebanon., Coelho RF; Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Gadia R; Hospital Sírio-Libanês, Brasília, Brazil., Khauli RB; American University of Beirut, Beirut, Lebanon., Dos Reis RB; Universidade de São Paulo, Ribeirão Preto, Brazil., Rojas RAL; Universidad de Chile, Santiago, Chile., Guimarães RG; A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil., Aldousari S; Kuwait University, Kuwait City, Kuwait., Ferrigno R; A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	JCO global oncology [JCO Glob Oncol] 2021 Apr; Vol. 7, pp. 523-529.
DOI:	10.1200/GO.20.00515
Abstrakt:	Purpose: A group of international urology and medical oncology experts developed and completed a survey on prostate cancer (PCa) in developing countries. The results are reviewed and summarized, and recommendations on consensus statements for very low-, low-, and intermediate-risk PCa focused on developing countries were developed. Methods: A panel of experts developed more than 300 survey questions of which 66 questions concern the principal areas of interest of this paper: very low, low, and intermediate risk of PCa in developing countries. A larger panel of 99 international multidisciplinary cancer experts voted on these questions to create the recommendations for treatment and follow-up for very low-, low-, and intermediate-risk PCa in areas of limited resources discussed in this manuscript. Results: The panel voted publicly but anonymously on the predefined questions. Each question was deemed consensus if 75% or more of the full panel had selected a particular answer. These answers are based on panelist opinion not a literature review or meta-analysis. For questions that refer to an area of limited resources, the recommendations consider cost-effectiveness and the possible therapies with easier and greater access. Each question had five to seven relevant answers including two nonanswers. The results were tabulated in real time. Conclusion: The voting results and recommendations presented in this document can be used by physicians to support management for very low, low, and intermediate risk of PCa in areas of limited resources. Individual clinical decision making should be supported by available data; however, as guidelines for treatment for very low, low, and intermediate risk of PCa in developing countries have not been developed, this document will serve as a point of reference when confronted with this disease. Competing Interests: Murilo de Almeida LuzConsulting or Advisory Role: Bayer, Janssen, Astellas PharmaSpeakers' Bureau: Bayer, Janssen, Astellas PharmaResearch Funding: Janssen, Bayer, Pfizer, Medivation, Myovant SciencesTravel, Accommodations, Expenses: Janssen, Astellas Pharma, Bayer, Roche Álvaro Sadek SarkisEmployment: Roche (I)Leadership: FerringHonoraria: Ferring, MSD, Genomic Health, Astellas PharmaConsulting or Advisory Role: FerringSpeakers' Bureau: FerringResearch Funding: FerringTravel, Accommodations, Expenses: Ferring Amr NowierResearch Funding: Astellas Pharma Ari Adamy JrSpeakers' Bureau: Janssen-Cilag, Astellas Pharma, Bayer, PfizerTravel, Accommodations, Expenses: Janssen-Cilag, Astellas Pharma Bruno Santos BenignoSpeakers' Bureau: Janssen-Cilag Eduardo Franco CarvalhalHonoraria: Janssen Leopoldo Alves Ribeiro FilhoConsulting or Advisory Role: FerringSpeakers' Bureau: Zodiac Pharma Lucas Mendes NogueiraConsulting or Advisory Role: BayerSpeakers' Bureau: Bayer, Astellas Pharma Marcelo Roberto Pereira FreitasConsulting or Advisory Role: Janssen Oncology, Zodiac PharmaSpeakers' Bureau: Astellas Pharma, Janssen Oncology Raja B. KhauliHonoraria: Astellas Pharma, Janssen, Algorithm, Hikma, LillyConsulting or Advisory Role: Astellas Pharma, HikmaSpeakers' Bureau: Algorithm, LillyResearch Funding: Astellas Pharma (Inst) Rodolfo Borges dos ReisConsulting or Advisory Role: JanssenSpeakers' Bureau: Janssen Rodrigo Antônio Ledezma RojasHonoraria: Ferring, Quanta SystemsConsulting or Advisory Role: Quanta Systems, FerringTravel, Accommodations, Expenses: Quanta SystemsNo other potential conflicts of interest were reported.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu